Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

166612

registered interest
date	27/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ambulance Services: City of Westminster
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is their assessment of the current London Ambulance Service response times to life-threatening incidents (category A calls) within the City of Westminster.
tabling member printed	Lord Hoyle
uin	HL3203
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The performance standard for ambulance trusts responding to Category A calls is that an ambulance resource should arrive within eight minutes of the call 75% of the time.</p><p> </p><p> </p><p> </p><p>We understand that this year to date (1 April 2014 -28 November 2014) the London Ambulance Service has achieved a response rate to ‘category A’ calls in Westminster of 69.58%.</p><p> </p><p> </p><p> </p><p>We are providing extra support to the National Health Service – including £50 million to help ambulance trusts with additional demand and help them to return to meeting the standard as quickly as possible.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:26:08 answering member 2000 label Biography information for Earl Howe
tabling member	1000 label Biography information for Lord Hoyle

166613

registered interest
date	27/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Palestinians
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what funds the European Union has contributed to the Palestinian National Security Forces during the last three years; what, if any, bilateral contribution they made; and whether they will propose that all such Forces be made accountable to the Palestinian people.
tabling member printed	Lord Hylton
uin	HL3204
answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>The EU does not directly fund the Palestinian National Security Forces. The UK and EU do fund projects aimed at supporting Palestinian state building. It is important that the Palestinian Authority continues work to build and maintain the institutions and economic underpinnings of the future Palestinian state, including transparency and good governance.</p> answering member printed Baroness Anelay of St Johns question first answered 04/12/2014 16:01:43 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	2018 label Biography information for Lord Hylton

166615

registered interest
date	27/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Ukraine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the remarks by Baroness Anelay of St Johns on 25 November (HL Deb, col 840), whether they supported the European Union's attempts to bring Ukraine within its sphere of influence; and what assessment they have made of the effect of those attempts on the present situation in Ukraine.
tabling member printed	Lord Pearson of Rannoch
uin	HL3206
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>This Government is a strong supporter of a closer EU-Ukraine relationship. The signing of the EU-Ukraine Association Agreement in June is a significant step towards closer relations, and a commitment by Ukraine to European norms and values. In the long term this could lead to EU membership for Ukraine, if that is what its people and government want, and if Ukraine is able to implement the wide ranging economic, political and judicial reforms that would be necessary to meet the demanding conditions of entry.</p><p>The crisis in Ukraine was not a result of the EU’s actions or the proposed signature of the Association Agreement in 2013. It is very clear where responsibility for the crisis lies – in Russia’s deliberate acts to destabilise its neighbour, its illegal annexation of Crimea and continued support of the separatists in eastern Ukraine.</p> answering member printed Baroness Anelay of St Johns question first answered 09/12/2014 14:34:09 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	3153 label Biography information for Lord Pearson of Rannoch

166618

registered interest
date	27/11/2014
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Entry Clearances: Imams
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the percentage of those Muslim imams admitted to the United Kingdom who cannot speak English; and what assessment they have made of the content of their teachings.
tabling member printed	Lord Pearson of Rannoch
uin	HL3209
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>There are three routes of entry to the UK for religious workers and ministers of religion. Those coming for longer term roles under Tier 2 of the Points Based System are required to demonstrate that that are proficient in English at level B2 (upper intermediate level) of the Common European Framework of Reference for Languages.</p><p>No assessment of English language is required for religious workers coming to fill temporary positions under Tier 5 of the Points Based System. Similarly those entering at short term visitors are not required to demonstrate proficiency in English language. We are actively reviewing the Immigration Rules for religious routes of entry including English language requirements.</p><p>This Government is committed to preventing the entry into the UK of individuals whose behaviours and views are not conducive to shared values such as democracy, the rule of law and tolerance of different faiths and beliefs. Since May 2010, the Home Secretary has excluded 84 preachers of hate. The Home Secretary uses these powers when justified and based on all available evidence. Where appropriate, this may include public statements and written material.</p><p> </p> answering member printed Lord Bates question first answered 08/12/2014 15:14:08 answering member 1091 label Biography information for Lord Bates
tabling member	3153 label Biography information for Lord Pearson of Rannoch

166619

registered interest
date	27/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Caribbean
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the answer by Lord Wallace of Saltaire on 24 November (HL Deb, col 678), in which specific islands and with which specific funding streams they are prioritising the Caribbean; and whether they consider it to be a priority.
tabling member printed	Lord Boateng
uin	HL3210
answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>The Caribbean is an important region for the UK, with which we have many historic and cultural ties, as well as shared interests and goals. As such, the UK wants to support the development of prosperous, resilient and secure economies in the region. We organise our work in this area under three broad categories: energy security, education, and security, all of which were discussed at the UK-Caribbean Forum Ministerial Forum in June of this year. <br><br>The Department for International Development (DfID) are currently launching a new set of development programmes which will run from 2015 to 2020. The UK has committed approximately £75 million between 2011 and 2015 and will invest a similar amount in the 2015-2020 period. The UK also accounts for approximately 15 per cent of the EU’s development funds, as well as being a major contributor to the World Bank and Caribbean Development Bank funds being deployed in the region, and has contributed some 48 per cent of the total funding for the Pilot Programme for Climate Resilience (PPCR). In addition, while DfID are the largest source of Government funding in the region, the Home Office, the Foreign and Commonwealth Office, Crown Prosecution Service, and the Ministry of Defence all fund activities in the region. <br><br>Specifically, DfID will deepen its development activities with Jamaica, Grenada, St Vincent and the Grenadines, St Lucia, Dominica and Antigua and Barbuda. It is our intent to support these countries efforts to return to growth while managing the risks from external shocks.</p> answering member printed Baroness Anelay of St Johns question first answered 04/12/2014 16:08:13 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	147 label Biography information for Lord Boateng

166620

registered interest
date	27/11/2014
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Homophobia
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what has been the number of recorded homophobic crimes in each of the last five years in England and Wales.
tabling member printed	Lord Black of Brentwood
uin	HL3211
answer	answer is ministerial correction date of answer 02/12/2014 answer text <p>The Home Office does not hold information specifically on homophobic crimes but does hold information on the number of hate crimes based on sexual orientation – which may also include crimes against heterosexuals (and perceived heterosexuals).</p><p>In 2011/12, 2012/13 and 2013/14 there were 4,364, 4,261 and 4,622 sexual orientation hate crimes recorded by the police in England and Wales (including the British Transport Police) respectively. The Home Office only holds data for the last three years.</p><p> </p> answering member printed Lord Bates question first answered 02/12/2014 15:31:56 answering member 1091 label Biography information for Lord Bates
tabling member	4171 label Biography information for Lord Black of Brentwood

166622

registered interest
date	27/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, in the light of the proposed re-evaluation of treatments on the Cancer Drugs Fund list, what assurances they can provide to patients with pancreatic cancer that the latest medicines will continue to be made available to them on the National Health Service.
tabling member printed	Baroness Masham of Ilton
uin	HL3213
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p><em> </em></p><p> </p><p>Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.</p><p> </p><p><br> NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br> We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p><p>Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.</p><p> </p><p><br> NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:28:28 answering member 2000 label Biography information for Earl Howe
tabling member	1850 label Biography information for Baroness Masham of Ilton

166623

registered interest
date	27/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what action they are taking to ensure that all treatments for advanced pancreatic cancer shown to be effective are made available to patients on the National Health Service.
tabling member printed	Baroness Masham of Ilton
uin	HL3214
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p><em> </em></p><p> </p><p>Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.</p><p> </p><p><br> NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br> We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p><p>Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.</p><p> </p><p><br> NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:29:26 answering member 2000 label Biography information for Earl Howe
tabling member	1850 label Biography information for Baroness Masham of Ilton

166624

registered interest
date	27/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what discussions they have had with NHS England regarding unmet need in respect of pancreatic cancer treatment when re-evaluating medicines on the Cancer Drugs Fund list.
tabling member printed	Baroness Masham of Ilton
uin	HL3215
answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>We have had no such discussions. These are matters for NHS England’s Cancer Drugs Fund clinical panel.</p><p> </p><p><br> The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>In making such decisions, the panel will take into account a number of factors, including unmet need.</p><p> </p><p><br> NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3216 question first answered 04/12/2014 16:06:53 answering member 2000 label Biography information for Earl Howe
tabling member	1850 label Biography information for Baroness Masham of Ilton

166625

registered interest
date	27/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what discussions they have had with NHS England regarding innovation in pancreatic cancer treatment when assessing medicines for inclusion on the Cancer Drugs Fund list.
tabling member printed	Baroness Masham of Ilton
uin	HL3216
answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>We have had no such discussions. These are matters for NHS England’s Cancer Drugs Fund clinical panel.</p><p> </p><p><br> The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>In making such decisions, the panel will take into account a number of factors, including unmet need.</p><p> </p><p><br> NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3215 question first answered 04/12/2014 16:06:53 answering member 2000 label Biography information for Earl Howe
tabling member	1850 label Biography information for Baroness Masham of Ilton